In this issue of Urology Times, we see interviews with several urologistswho have chosen to change paths in mid-career (see article, page 1). Havinggone through many of these issues myself, a few words of caution are inorder. Everyone goes through a period when they at least consider major changes,either because they have "been there, done that" and want somethingnew, or perhaps changes are forced upon them for personal or health reasons.Most of us have gone through the medical tract in life on somewhat of astraightaway. We go from high school to college, from college to medicalschool, from medical school to surgical and urology training, and embarkon our career. After several years of practice, looking at other fieldsand endeavors may be a natural progression for many of us.
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.